ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2805

Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls

Noha Elemam1, Mahmood Hachim 1, Suad Hannawi 2 and Azzam Maghazachi 1, 1Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, Sharjah, United Arab Emirates, 2Ministry of Health and Prevention-UAE, Department of Rheumatology, Dubai, United Arab Emirates

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Gene Expression and biomarkers, natural killer (NK) cells, Rheumatoid arthritis (RA)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T110: Innate Immunity (2804–2809)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune diseases (1-3% of the world’s population). RA is a prototypic inflammatory disease, being characterized by an altered state of homeostasis, in which immunological stimulation and unwanted inflammation prevail (Pincus, Brooks et al. 1994). The molecular triggers for the development of RA in healthy subjects are still not clearly defined. Identification of RA specific transcriptional signature can shed the light on the molecular pathogenesis of RA. Such signature facilitates the selection of biomarkers that can be used for early detection of RA and prediction of effectiveness of RA treatment. Most of the current transcriptome analyses in RA had focused on whole peripheral blood mononuclear cells (PBMCs). Few studies have indicated that natural killer (NK) cells may play either a pathogenic or a protective role in RA (Shegarfi, Naddafi et al. 2012, Yap, Tee et al. 2018). Hence, in this study we aimed at exploring NK cell markers that could possibly be used to aid in evaluating the differences among healthy controls and RA patients.

Methods: Publicly available transcriptome dataset (GSE93777) of sorted immune cells from RA patients and healthy volunteers were reanalyzed using in house pipeline for normalization and filtration of the raw probes’ expression. Gene Set Enrichment analysis was used to identify genes that are differentially expressed (DEG) between different immune cells as compared to NK cells. Next, DEG between NK cells of RA patients and healthy controls were selected. Both lists of identified DEG were validated in peripheral blood collected from healthy controls and RA patients. Whole blood samples were collected from the recruited 11 RA patients (satisfying the 2010 ACR/EULAR classification criteria for RA) and 10 healthy controls (with no diagnosis of autoimmune diseases). Then, PBMCs were separated by Ficoll density gradient method, while NK cells were isolated using RosetteSep negative selection method. RNA was extracted and gene expression was assessed using qRT-PCR. Statistical analysis was done using Mann-Whitney test. Binary regression test was used to predict the probabilities of being a case based on the values of the selected genes.

Results: Similar to CD56, a known marker for NK cells, and interferon gamma (IFN-γ), a prototype cytokine secreted by these cells, PECAM-1, IBTK, ITGB7, and RELA were expressed in  NK cells (Figure 1A). Furthermore, chemokine ligands and receptors (CCR4, CXCL10, CXCL16, CXCR1, CXCR2, CXCR6) were specifically expressed by NK cells in comparison to PBMCs (Figure 1B). Additionally, as predicted by bioinformatics (Figure 2A), CXCL16, CD56, PECAM-1, ITGB7, BTK, TLR10, and IL-1β were significantly upregulated in NK cells of RA patients when compared to healthy controls, whereas CCL2 was downregulated (Figure 2B). In this study, we applied a logistic regression model using some of the identified NK genes expression (RELA, BTK, IL-1β, CKLF, PECAM-1, TLR10, IL1RN, IFN-γ) where it showed a good prediction power as predictors for RA.

Conclusion: Gene expression of these molecules; namely CXCL16, CD56, PECAM-1, ITGB7, BTK, TLR10 and IL-1β, in NK cells might be used as promising biomarkers for RA disease.

Figure 1. Differentially expressed genes -A- and chemokine ligands/receptors -B- between PBMCs and NK cells.

Figure 2. -A- In silico Gene Set Enrichment Analysis identified DEG between NK cells of RA patients and healthy controls. -B- Ex-vivo validation showed that NK cells from recruited RA patients showed differential expression of the predicted genes compared to healthy individuals.


Disclosure: N. Elemam, None; M. Hachim, None; S. Hannawi, None; A. Maghazachi, None.

To cite this abstract in AMA style:

Elemam N, Hachim M, Hannawi S, Maghazachi A. Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/natural-killer-cells-gene-expression-can-differentiate-rheumatoid-arthritis-patients-from-healthy-controls/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/natural-killer-cells-gene-expression-can-differentiate-rheumatoid-arthritis-patients-from-healthy-controls/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology